In vitro susceptibility of Stenotrophomonas maltophilia isolates:: comparison of disc diffusion, Etest and agar dilution methods

被引:76
作者
Nicodemo, AC [1 ]
Araujo, MRE
Ruiz, AS
Gales, AC
机构
[1] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-05508 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil
关键词
susceptibility testing; drug resistance; S; maltophilia;
D O I
10.1093/jac/dkh128
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The disc diffusion, Etest and agar dilution techniques were compared to evaluate the antimicrobial susceptibility profile of 70 Stenotrophomonas maltophilia isolates to seven antimicrobial agents. The S. maltophilia isolates were consecutively collected from May 2000 to May 2002 from individual patients, who were hospitalized in a private Brazilian hospital. The antimicrobial susceptibility tests were carried out and interpreted according to the National Committee for Clinical Laboratory Standards (NCCLS) recommendations. The Etest was carried out according to the manufacturer's instructions. There was good agreement among the distinct susceptibility testing results for chloramphenicol, doxycycline, gatifloxacin, trimethoprim-sulfamethoxazole and ticarcillin-clavulanate, suggesting that the disc diffusion and Etest methods are reliable for testing this group of antimicrobials against S. maltophilia. In contrast, a weak correlation was found between the disc diffusion and agar dilution techniques for testing polymyxin B and colistin with unacceptable very major error rates (18.1% and 22.7% for polymyxin B and colistin, respectively). Trimethoprim- sulfamethoxazole (MIC50, 0.06 mg/L; 98.5% susceptible) and gatifloxacin (MIC50, 0.12 mg/L; 98.5% susceptible) were the most potent antimicrobial agents tested against S. maltophilia isolates. In contrast, the worst in vitro activity was found for ticarcillin-clavulanate (MIC50, 16 mg/L; 59.1% susceptible). Although our results confirm that trimethoprim-sulfamethoxazole, gatifloxacin and doxycycline have an excellent in vitro activity against S. maltophilia, further clinical studies are necessary to evaluate the clinical efficacy of these compounds for the treatment of S. maltophilia infections, since no randomized controlled trials have been carried out and no correlation between the clinical response and susceptibility testing results has been reported.
引用
收藏
页码:604 / 608
页数:5
相关论文
共 26 条
[1]   In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates - Comparison of the agar dilution method with the E-test and two agar diffusion methods [J].
Arpi, M ;
Victor, MA ;
Mortensen, I ;
Gottschau, A ;
Bruun, B .
APMIS, 1996, 104 (02) :108-114
[2]   Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods [J].
Biedenbach, DJ ;
Croco, MAT ;
Barrett, TJ ;
Jones, RN .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (06) :428-431
[3]   Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates [J].
Bonfiglio, G ;
Cascone, C ;
Azzarelli, C ;
Cafiso, V ;
Marchetti, F ;
Stefani, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (01) :115-117
[4]   Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates [J].
Cantón, R ;
Valdezate, S ;
Vindel, A ;
Del Saz, BS ;
Maíz, L ;
Baquero, F .
PEDIATRIC PULMONOLOGY, 2003, 35 (02) :99-107
[5]   Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients:: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999) [J].
Gales, AC ;
Jones, RN ;
Forward, KR ;
Liñares, J ;
Sader, HS ;
Verhoef, J .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S104-S113
[6]   Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines [J].
Gales, AC ;
Reis, AO ;
Jones, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (01) :183-190
[7]   Stenotrophomonas maltophilia: Emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model [J].
Garrison, MW ;
Anderson, DE ;
Campbell, DM ;
Carroll, KC ;
Malone, CL ;
Anderson, JD ;
Hollis, RJ ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2859-2864
[8]   Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia [J].
Giamarellos-Bourboulis, EJ ;
Karnesis, L ;
Giamarellou, H .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (03) :259-263
[9]   INVITRO SUSCEPTIBILITY OF 33 CLINICAL CASE ISOLATES OF XANTHOMONAS-MALTOPHILIA - INCONSISTENT CORRELATION OF AGAR DILUTION AND OF DISK DIFFUSION TEST-RESULTS [J].
HOHL, P ;
FREI, R ;
AUBRY, P .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1991, 14 (05) :447-450
[10]   Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii [J].
Levin, AS ;
Barone, AA ;
Penço, J ;
Santos, MV ;
Marinho, IS ;
Arruda, EAG ;
Manrique, EI ;
Costa, SF .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1008-1011